**Background of PDLIM5 Antibody**
PDLIM5 (PDZ and LIM domain protein 5), also known as LIMK1-binding protein or ENH2. is a cytoskeletal protein belonging to the ALP/Enigma family. It contains a PDZ domain at the N-terminus and three LIM domains at the C-terminus, enabling interactions with various signaling molecules, kinases, and structural proteins. PDLIM5 is implicated in regulating cell adhesion, cytoskeletal organization, and intracellular signaling pathways, particularly those involving actin dynamics. It also plays roles in neuronal development, cardiac function, and cancer progression.
Antibodies targeting PDLIM5 are essential tools for studying its expression, localization, and function in biological systems. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect PDLIM5 in tissues or cultured cells. Research utilizing these antibodies has linked PDLIM5 dysregulation to neuropsychiatric disorders (e.g., schizophrenia), cardiovascular diseases, and tumor metastasis, highlighting its potential as a therapeutic or diagnostic marker.
Commercial PDLIM5 antibodies are typically raised in hosts like rabbits or mice, with validation in specific applications. Researchers must verify antibody specificity using knockout controls or peptide blocking assays due to possible cross-reactivity with homologous LIM-domain proteins. Recent studies continue to explore PDLIM5's role in mechanotransduction and disease mechanisms, driving demand for reliable antibodies in experimental and clinical contexts.